TABLE 3

The hemodynamic, echocardiography, and SPECT findings

Baseline
After 16 weeks
PlaceboRosiglitazonePlaceboRosiglitazone
Systolic blood pressure (mmHg)145 ± 19143 ± 17141 ± 21140 ± 17
Diastolic blood pressure (mmHg)79 ± 877 ± 1075 ± 876 ± 9
Heart rate/min66 ± 1065 ± 1163 ± 967 ± 10*
Rate pressure product (mmHg/min)9,525 ± 1,7209,216 ± 2,0038,914 ± 1,6339,339 ± 2,022
Ejection fraction (%)66 ± 662 ± 766 ± 662 ± 8
Myocardial workload (mmHg · l−1 · min−1)931.7 ± 195.5866.0 ± 177.1882.3 ± 147.0847.5 ± 145.0
Myocardial workload per gram of tissue (mmHg · l−1 · g−1 · min−1)3.96 ± 0.893.75 ± 1.033.74 ± 0.713.64 ± 0.88
Wall stress (mmHg)62.3 ± 11.669.4 ± 24.759.8 ± 12.069.4 ± 23.2
Ischemic score7.2 + 4.58.0 + 4.87.7 + 3.27.8 + 4.3
  • Data are means ± SD.

  • *

    * P = 0.038 change in the placebo group vs. the rosiglitazone group;

  • P = 0.030 difference between the groups at baseline;

  • P = 0.047 difference between the groups after intervention.